Corrigendum
===========

The authors regret that there are errors in their original paper.

1.  1\. The following shows where original text has been removed (strikethrough) and new wording introduced (underlined).

Page 3, section on Berinert^®^
------------------------------

In 2009, the [US]{.ul} FDA approved Berinert^®^ (CSL Behring), a pasteurized plasma-derived C1-INH concentrate, available for intravenous (IV) administration in patients needing on-demand therapy. This drug was [also]{.ul} ~~not~~ approved for short-term prophylaxis [in the EU in 2013.]{.ul} ~~but is used off-label for this purpose.~~

> The following reference from the Head of Medicine website (EU approval document) should also be added to this statement: <https://mri.cts-mrp.eu/Human/Downloads/DE_H_0481_003_PAR.pdf>

Page 5, section on Haegarda^®^
------------------------------

C1-INH (SC) ~~Haegarda^®^~~

Haegarda^®^ [and Berinert]{.ul}^[®]{.ul}^[2000/3000]{.ul} (CSL Behring) [were approved (US and EU)]{.ul} ~~was approved by the FDA~~ in 2017 as the first subcutaneous C1 inhibitor concentrate, also indicated for self-administration, at the dose of 60 IU/kg twice weekly. ~~Nevertheless, the European Medicines Agency did not formally approve the marketing of the drug~~.^29^

1.  2\. [Table 1](#t1-dic-2019-11-2){ref-type="table"} lists two products Berinert^®^ and Haegarda^®^ on separate lines; however, they should be grouped together as follows:

    Drug nameActive substanceType and actionAdministrationIndicationT1/2Berinert^®^, CSL BehringC1-INHPlasma-derived C1-INH concentrate pasteurized, nanofilteredIVOn-demand, short-term prophylaxis36--48 hoursBerinert^®^ 2000/3000 (Haegarda^®^ brand name in the United States and Canada)C1-INHPlasma-derived C1-INH concentrate pasteurized, nanofilteredSCLong-term prophylaxis69 hours
